USFDA issues ‘zero’ 483 observations for Hikal’s Bengaluru plant

10 Jan 2017 Evaluate

Hikal’s active pharmaceutical ingredient (API) and Intermediates manufacturing facility located at Jigani, Bengaluru was recently inspected by the US Food and Drug Administration (USFDA) in compliance with their requirements. At the end of the successful inspection, the company has been informed by the Investigator that ‘zero’ 483 observations were issued. This was a routine inspection by the USFDA.

Hikal is engaged in R&D, manufacturing and marketing of fine chemicals for the Pharmaceutical and Agrochemical industries. It collaborates with innovator companies and offer solutions in Contract Research, Custom Synthesis and Custom Manufacturing.

Hikal Share Price

242.40 -10.55 (-4.17%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×